The 10-second takeaway
For the quarter ended June 30 (Q2), Watson Pharmaceuticals met expectations on revenues and beat slightly on earnings per share.
Compared to the prior-year quarter, revenue increased significantly and GAAP earnings per share dropped to a loss.
Gross margins increased, operating margins increased, net margins dropped.
Watson Pharmaceuticals recorded revenue of $1.36 billion. The 19 analysts polled by S&P Capital IQ hoped for revenue of $1.35 billion on the same basis. GAAP reported sales were 25% higher than the prior-year quarter's $1.08 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $1.42. The 22 earnings estimates compiled by S&P Capital IQ predicted $1.39 per share. GAAP EPS were -$0.49 for Q2 versus $0.42 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 44.4%, 90 basis points better than the prior-year quarter. Operating margin was 13.0%, 60 basis points better than the prior-year quarter. Net margin was -4.6%, 950 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $1.29 billion. On the bottom line, the average EPS estimate is $1.35.
Next year's average estimate for revenue is $5.53 billion. The average EPS estimate is $5.77.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 190 members out of 214 rating the stock outperform, and 24 members rating it underperform. Among 73 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 67 give Watson Pharmaceuticals a green thumbs-up, and six give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Watson Pharmaceuticals is outperform, with an average price target of $85.60.
- Add Watson Pharmaceuticals to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.